Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 6/20 | 0.45 |
| ▸ | PTGES | O14684 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | APAF1 | O14727 | 1/20 | 0.36 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16700525 | 0.84 | ALOX5 (0.45) | ALOX5PTGESCYP19A1TSHRALDH1A1 | |
| SCHEMBL16700699 | 0.82 | CYP19A1 (0.49) | CYP19A1POLBTP53 | |
| SCHEMBL2683467 | 0.78 | ALDH1A1 (0.46) | ALOX5TSHRALDH1A1TP53 | |
| SCHEMBL2688524 | 0.74 | TSHR (0.41) | TSHRALDH1A1TP53 | |
| SCHEMBL5771514 | 0.72 | ALOX5 (0.53) | ALOX5PTGESTSHRALDH1A1POLB | |
| SCHEMBL23856156 | 0.71 | MAOB (0.39) | CYP19A1TSHRALDH1A1USP2 | |
| SCHEMBL2688091 | 0.71 | LMNA (0.45) | CYP19A1ALDH1A1USP2POLB | |
| SCHEMBL15465704 | 0.70 | HTT (0.54) | ALOX5PTGESTSHRALDH1A1POLB | |
| SCHEMBL15919052 | 0.70 | TSHR (0.36) | ALOX5PTGESTSHRALDH1A1POLB | |
| SCHEMBL16700712 | 0.69 | L3MBTL1 (0.43) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321738-B2 | N-alkyltriazole compounds as LPAR antagonists | HOFFMAN-LA ROCHE INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150133511-A1 | N-ALKYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133511-A1 | N-ALKYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS | LPAR1, LPAR2, LPAR3 | ALOX5 224/4885PTGES 846/4885CYP19A1 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.